Investigational Drug Information for Bucindolol
✉ Email this page to a colleague
What is the drug development status for Bucindolol?
Bucindolol is an investigational drug.
There have been 3 clinical trials for Bucindolol.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 1994.
The most common disease conditions in clinical trials are Heart Failure, Cardiovascular Diseases, and Atrial Flutter. The leading clinical trial sponsors are National Heart, Lung, and Blood Institute (NHLBI), University of Oxford, and Royal Brompton & Harefield NHS Foundation Trust.
Summary for Bucindolol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,238 |
| WIPO Patent Applications | 786 |
| Japanese Patent Applications | 369 |
| Clinical Trial Progress | Phase 3 (1994-06-01) |
| Vendors | 0 |
Recent Clinical Trials for Bucindolol
| Title | Sponsor | Phase |
|---|---|---|
| Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure | Medtronic | Phase 2 |
| Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure | ARCA Biopharma, Inc. | Phase 2 |
| Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure | University of Oxford |
Clinical Trial Summary for Bucindolol
Top disease conditions for Bucindolol
Top clinical trial sponsors for Bucindolol
US Patents for Bucindolol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
